[{"path":[]},{"path":"https://www.pattern.institute/alz/CODE_OF_CONDUCT.html","id":"our-pledge","dir":"","previous_headings":"","what":"Our Pledge","title":"Contributor Covenant Code of Conduct","text":"members, contributors, leaders pledge make participation community harassment-free experience everyone, regardless age, body size, visible invisible disability, ethnicity, sex characteristics, gender identity expression, level experience, education, socio-economic status, nationality, personal appearance, race, caste, color, religion, sexual identity orientation. pledge act interact ways contribute open, welcoming, diverse, inclusive, healthy community.","code":""},{"path":"https://www.pattern.institute/alz/CODE_OF_CONDUCT.html","id":"our-standards","dir":"","previous_headings":"","what":"Our Standards","title":"Contributor Covenant Code of Conduct","text":"Examples behavior contributes positive environment community include: Demonstrating empathy kindness toward people respectful differing opinions, viewpoints, experiences Giving gracefully accepting constructive feedback Accepting responsibility apologizing affected mistakes, learning experience Focusing best just us individuals, overall community Examples unacceptable behavior include: use sexualized language imagery, sexual attention advances kind Trolling, insulting derogatory comments, personal political attacks Public private harassment Publishing others’ private information, physical email address, without explicit permission conduct reasonably considered inappropriate professional setting","code":""},{"path":"https://www.pattern.institute/alz/CODE_OF_CONDUCT.html","id":"enforcement-responsibilities","dir":"","previous_headings":"","what":"Enforcement Responsibilities","title":"Contributor Covenant Code of Conduct","text":"Community leaders responsible clarifying enforcing standards acceptable behavior take appropriate fair corrective action response behavior deem inappropriate, threatening, offensive, harmful. Community leaders right responsibility remove, edit, reject comments, commits, code, wiki edits, issues, contributions aligned Code Conduct, communicate reasons moderation decisions appropriate.","code":""},{"path":"https://www.pattern.institute/alz/CODE_OF_CONDUCT.html","id":"scope","dir":"","previous_headings":"","what":"Scope","title":"Contributor Covenant Code of Conduct","text":"Code Conduct applies within community spaces, also applies individual officially representing community public spaces. Examples representing community include using official e-mail address, posting via official social media account, acting appointed representative online offline event.","code":""},{"path":"https://www.pattern.institute/alz/CODE_OF_CONDUCT.html","id":"enforcement","dir":"","previous_headings":"","what":"Enforcement","title":"Contributor Covenant Code of Conduct","text":"Instances abusive, harassing, otherwise unacceptable behavior may reported community leaders responsible enforcement rmagno@pattern.institute. complaints reviewed investigated promptly fairly. community leaders obligated respect privacy security reporter incident.","code":""},{"path":"https://www.pattern.institute/alz/CODE_OF_CONDUCT.html","id":"enforcement-guidelines","dir":"","previous_headings":"","what":"Enforcement Guidelines","title":"Contributor Covenant Code of Conduct","text":"Community leaders follow Community Impact Guidelines determining consequences action deem violation Code Conduct:","code":""},{"path":"https://www.pattern.institute/alz/CODE_OF_CONDUCT.html","id":"id_1-correction","dir":"","previous_headings":"Enforcement Guidelines","what":"1. Correction","title":"Contributor Covenant Code of Conduct","text":"Community Impact: Use inappropriate language behavior deemed unprofessional unwelcome community. Consequence: private, written warning community leaders, providing clarity around nature violation explanation behavior inappropriate. public apology may requested.","code":""},{"path":"https://www.pattern.institute/alz/CODE_OF_CONDUCT.html","id":"id_2-warning","dir":"","previous_headings":"Enforcement Guidelines","what":"2. Warning","title":"Contributor Covenant Code of Conduct","text":"Community Impact: violation single incident series actions. Consequence: warning consequences continued behavior. interaction people involved, including unsolicited interaction enforcing Code Conduct, specified period time. includes avoiding interactions community spaces well external channels like social media. Violating terms may lead temporary permanent ban.","code":""},{"path":"https://www.pattern.institute/alz/CODE_OF_CONDUCT.html","id":"id_3-temporary-ban","dir":"","previous_headings":"Enforcement Guidelines","what":"3. Temporary Ban","title":"Contributor Covenant Code of Conduct","text":"Community Impact: serious violation community standards, including sustained inappropriate behavior. Consequence: temporary ban sort interaction public communication community specified period time. public private interaction people involved, including unsolicited interaction enforcing Code Conduct, allowed period. Violating terms may lead permanent ban.","code":""},{"path":"https://www.pattern.institute/alz/CODE_OF_CONDUCT.html","id":"id_4-permanent-ban","dir":"","previous_headings":"Enforcement Guidelines","what":"4. Permanent Ban","title":"Contributor Covenant Code of Conduct","text":"Community Impact: Demonstrating pattern violation community standards, including sustained inappropriate behavior, harassment individual, aggression toward disparagement classes individuals. Consequence: permanent ban sort public interaction within community.","code":""},{"path":"https://www.pattern.institute/alz/CODE_OF_CONDUCT.html","id":"attribution","dir":"","previous_headings":"","what":"Attribution","title":"Contributor Covenant Code of Conduct","text":"Code Conduct adapted Contributor Covenant, version 2.1, available https://www.contributor-covenant.org/version/2/1/code_of_conduct.html. Community Impact Guidelines inspired [Mozilla’s code conduct enforcement ladder][https://github.com/mozilla/inclusion]. answers common questions code conduct, see FAQ https://www.contributor-covenant.org/faq. Translations available https://www.contributor-covenant.org/translations.","code":""},{"path":"https://www.pattern.institute/alz/CONTRIBUTING.html","id":null,"dir":"","previous_headings":"","what":"Contributing to mgi.report.reader","title":"Contributing to mgi.report.reader","text":"outlines propose change alz.","code":""},{"path":"https://www.pattern.institute/alz/CONTRIBUTING.html","id":"fixing-typos","dir":"","previous_headings":"","what":"Fixing typos","title":"Contributing to mgi.report.reader","text":"can fix typos, spelling mistakes, grammatical errors documentation directly using GitHub web interface, long changes made source file. generally means ’ll need edit roxygen2 comments .R, .Rd file. can find .R file generates .Rd reading comment first line.","code":""},{"path":"https://www.pattern.institute/alz/CONTRIBUTING.html","id":"bigger-changes","dir":"","previous_headings":"","what":"Bigger changes","title":"Contributing to mgi.report.reader","text":"want make bigger change, ’s good idea first file issue make sure someone team agrees ’s needed. ’ve found bug, please file issue illustrates bug minimal reprex (also help write unit test, needed).","code":""},{"path":"https://www.pattern.institute/alz/CONTRIBUTING.html","id":"pull-request-process","dir":"","previous_headings":"Bigger changes","what":"Pull request process","title":"Contributing to mgi.report.reader","text":"Fork package clone onto computer. haven’t done , recommend using usethis::create_from_github(\"patterninstitute/alz\", fork = TRUE). Install development dependencies devtools::install_dev_deps(), make sure package passes R CMD check running devtools::check(). R CMD check doesn’t pass cleanly, ’s good idea ask help continuing. Create Git branch pull request (PR). recommend using usethis::pr_init(\"brief-description--change\"). Make changes, commit git, create PR running usethis::pr_push(), following prompts browser. title PR briefly describe change. body PR contain Fixes #issue-number. user-facing changes, add bullet top NEWS.md (.e. just first header). Follow style described https://style.tidyverse.org/news.html.","code":""},{"path":"https://www.pattern.institute/alz/CONTRIBUTING.html","id":"code-style","dir":"","previous_headings":"Bigger changes","what":"Code style","title":"Contributing to mgi.report.reader","text":"use roxygen2, Markdown syntax, documentation. use testthat unit tests. Contributions test cases included easier accept.","code":""},{"path":"https://www.pattern.institute/alz/CONTRIBUTING.html","id":"code-of-conduct","dir":"","previous_headings":"","what":"Code of Conduct","title":"Contributing to mgi.report.reader","text":"Please note alz project released Contributor Code Conduct. contributing project agree abide terms.","code":""},{"path":"https://www.pattern.institute/alz/LICENSE.html","id":null,"dir":"","previous_headings":"","what":"GNU Affero General Public License","title":"GNU Affero General Public License","text":"Version 3, 19 November 2007 Copyright (C) 2007 Free Software Foundation, Inc. <https://fsf.org/> Everyone permitted copy distribute verbatim copies license document, changing allowed.","code":""},{"path":"https://www.pattern.institute/alz/LICENSE.html","id":"preamble","dir":"","previous_headings":"","what":"Preamble","title":"GNU Affero General Public License","text":"GNU Affero General Public License free, copyleft license software kinds works, specifically designed ensure cooperation community case network server software. licenses software practical works designed take away freedom share change works. contrast, General Public Licenses intended guarantee freedom share change versions program–make sure remains free software users. speak free software, referring freedom, price. General Public Licenses designed make sure freedom distribute copies free software (charge wish), receive source code can get want , can change software use pieces new free programs, know can things. Developers use General Public Licenses protect rights two steps: (1) assert copyright software, (2) offer License gives legal permission copy, distribute /modify software. secondary benefit defending users’ freedom improvements made alternate versions program, receive widespread use, become available developers incorporate. Many developers free software heartened encouraged resulting cooperation. However, case software used network servers, result may fail come . GNU General Public License permits making modified version letting public access server without ever releasing source code public. GNU Affero General Public License designed specifically ensure , cases, modified source code becomes available community. requires operator network server provide source code modified version running users server. Therefore, public use modified version, publicly accessible server, gives public access source code modified version. older license, called Affero General Public License published Affero, designed accomplish similar goals. different license, version Affero GPL, Affero released new version Affero GPL permits relicensing license. precise terms conditions copying, distribution modification follow.","code":""},{"path":[]},{"path":"https://www.pattern.institute/alz/LICENSE.html","id":"id_0-definitions","dir":"","previous_headings":"TERMS AND CONDITIONS","what":"0. Definitions.","title":"GNU Affero General Public License","text":"“License” refers version 3 GNU Affero General Public License. “Copyright” also means copyright-like laws apply kinds works, semiconductor masks. “Program” refers copyrightable work licensed License. licensee addressed “”. “Licensees” “recipients” may individuals organizations. “modify” work means copy adapt part work fashion requiring copyright permission, making exact copy. resulting work called “modified version” earlier work work “based ” earlier work. “covered work” means either unmodified Program work based Program. “propagate” work means anything , without permission, make directly secondarily liable infringement applicable copyright law, except executing computer modifying private copy. Propagation includes copying, distribution (without modification), making available public, countries activities well. “convey” work means kind propagation enables parties make receive copies. Mere interaction user computer network, transfer copy, conveying. interactive user interface displays “Appropriate Legal Notices” extent includes convenient prominently visible feature (1) displays appropriate copyright notice, (2) tells user warranty work (except extent warranties provided), licensees may convey work License, view copy License. interface presents list user commands options, menu, prominent item list meets criterion.","code":""},{"path":"https://www.pattern.institute/alz/LICENSE.html","id":"id_1-source-code","dir":"","previous_headings":"TERMS AND CONDITIONS","what":"1. Source Code.","title":"GNU Affero General Public License","text":"“source code” work means preferred form work making modifications . “Object code” means non-source form work. “Standard Interface” means interface either official standard defined recognized standards body, , case interfaces specified particular programming language, one widely used among developers working language. “System Libraries” executable work include anything, work whole, () included normal form packaging Major Component, part Major Component, (b) serves enable use work Major Component, implement Standard Interface implementation available public source code form. “Major Component”, context, means major essential component (kernel, window system, ) specific operating system () executable work runs, compiler used produce work, object code interpreter used run . “Corresponding Source” work object code form means source code needed generate, install, (executable work) run object code modify work, including scripts control activities. However, include work’s System Libraries, general-purpose tools generally available free programs used unmodified performing activities part work. example, Corresponding Source includes interface definition files associated source files work, source code shared libraries dynamically linked subprograms work specifically designed require, intimate data communication control flow subprograms parts work. Corresponding Source need include anything users can regenerate automatically parts Corresponding Source. Corresponding Source work source code form work.","code":""},{"path":"https://www.pattern.institute/alz/LICENSE.html","id":"id_2-basic-permissions","dir":"","previous_headings":"TERMS AND CONDITIONS","what":"2. Basic Permissions.","title":"GNU Affero General Public License","text":"rights granted License granted term copyright Program, irrevocable provided stated conditions met. License explicitly affirms unlimited permission run unmodified Program. output running covered work covered License output, given content, constitutes covered work. License acknowledges rights fair use equivalent, provided copyright law. may make, run propagate covered works convey, without conditions long license otherwise remains force. may convey covered works others sole purpose make modifications exclusively , provide facilities running works, provided comply terms License conveying material control copyright. thus making running covered works must exclusively behalf, direction control, terms prohibit making copies copyrighted material outside relationship . Conveying circumstances permitted solely conditions stated . Sublicensing allowed; section 10 makes unnecessary.","code":""},{"path":"https://www.pattern.institute/alz/LICENSE.html","id":"id_3-protecting-users-legal-rights-from-anti-circumvention-law","dir":"","previous_headings":"TERMS AND CONDITIONS","what":"3. Protecting Users’ Legal Rights From Anti-Circumvention Law.","title":"GNU Affero General Public License","text":"covered work shall deemed part effective technological measure applicable law fulfilling obligations article 11 WIPO copyright treaty adopted 20 December 1996, similar laws prohibiting restricting circumvention measures. convey covered work, waive legal power forbid circumvention technological measures extent circumvention effected exercising rights License respect covered work, disclaim intention limit operation modification work means enforcing, work’s users, third parties’ legal rights forbid circumvention technological measures.","code":""},{"path":"https://www.pattern.institute/alz/LICENSE.html","id":"id_4-conveying-verbatim-copies","dir":"","previous_headings":"TERMS AND CONDITIONS","what":"4. Conveying Verbatim Copies.","title":"GNU Affero General Public License","text":"may convey verbatim copies Program’s source code receive , medium, provided conspicuously appropriately publish copy appropriate copyright notice; keep intact notices stating License non-permissive terms added accord section 7 apply code; keep intact notices absence warranty; give recipients copy License along Program. may charge price price copy convey, may offer support warranty protection fee.","code":""},{"path":"https://www.pattern.institute/alz/LICENSE.html","id":"id_5-conveying-modified-source-versions","dir":"","previous_headings":"TERMS AND CONDITIONS","what":"5. Conveying Modified Source Versions.","title":"GNU Affero General Public License","text":"may convey work based Program, modifications produce Program, form source code terms section 4, provided also meet conditions: work must carry prominent notices stating modified , giving relevant date. work must carry prominent notices stating released License conditions added section 7. requirement modifies requirement section 4 “keep intact notices”. must license entire work, whole, License anyone comes possession copy. License therefore apply, along applicable section 7 additional terms, whole work, parts, regardless packaged. License gives permission license work way, invalidate permission separately received . work interactive user interfaces, must display Appropriate Legal Notices; however, Program interactive interfaces display Appropriate Legal Notices, work need make . compilation covered work separate independent works, nature extensions covered work, combined form larger program, volume storage distribution medium, called “aggregate” compilation resulting copyright used limit access legal rights compilation’s users beyond individual works permit. Inclusion covered work aggregate cause License apply parts aggregate.","code":""},{"path":"https://www.pattern.institute/alz/LICENSE.html","id":"id_6-conveying-non-source-forms","dir":"","previous_headings":"TERMS AND CONDITIONS","what":"6. Conveying Non-Source Forms.","title":"GNU Affero General Public License","text":"may convey covered work object code form terms sections 4 5, provided also convey machine-readable Corresponding Source terms License, one ways: Convey object code , embodied , physical product (including physical distribution medium), accompanied Corresponding Source fixed durable physical medium customarily used software interchange. Convey object code , embodied , physical product (including physical distribution medium), accompanied written offer, valid least three years valid long offer spare parts customer support product model, give anyone possesses object code either (1) copy Corresponding Source software product covered License, durable physical medium customarily used software interchange, price reasonable cost physically performing conveying source, (2) access copy Corresponding Source network server charge. Convey individual copies object code copy written offer provide Corresponding Source. alternative allowed occasionally noncommercially, received object code offer, accord subsection 6b. Convey object code offering access designated place (gratis charge), offer equivalent access Corresponding Source way place charge. need require recipients copy Corresponding Source along object code. place copy object code network server, Corresponding Source may different server (operated third party) supports equivalent copying facilities, provided maintain clear directions next object code saying find Corresponding Source. Regardless server hosts Corresponding Source, remain obligated ensure available long needed satisfy requirements. Convey object code using peer--peer transmission, provided inform peers object code Corresponding Source work offered general public charge subsection 6d. separable portion object code, whose source code excluded Corresponding Source System Library, need included conveying object code work. “User Product” either (1) “consumer product”, means tangible personal property normally used personal, family, household purposes, (2) anything designed sold incorporation dwelling. determining whether product consumer product, doubtful cases shall resolved favor coverage. particular product received particular user, “normally used” refers typical common use class product, regardless status particular user way particular user actually uses, expects expected use, product. product consumer product regardless whether product substantial commercial, industrial non-consumer uses, unless uses represent significant mode use product. “Installation Information” User Product means methods, procedures, authorization keys, information required install execute modified versions covered work User Product modified version Corresponding Source. information must suffice ensure continued functioning modified object code case prevented interfered solely modification made. convey object code work section , , specifically use , User Product, conveying occurs part transaction right possession use User Product transferred recipient perpetuity fixed term (regardless transaction characterized), Corresponding Source conveyed section must accompanied Installation Information. requirement apply neither third party retains ability install modified object code User Product (example, work installed ROM). requirement provide Installation Information include requirement continue provide support service, warranty, updates work modified installed recipient, User Product modified installed. Access network may denied modification materially adversely affects operation network violates rules protocols communication across network. Corresponding Source conveyed, Installation Information provided, accord section must format publicly documented (implementation available public source code form), must require special password key unpacking, reading copying.","code":""},{"path":"https://www.pattern.institute/alz/LICENSE.html","id":"id_7-additional-terms","dir":"","previous_headings":"TERMS AND CONDITIONS","what":"7. Additional Terms.","title":"GNU Affero General Public License","text":"“Additional permissions” terms supplement terms License making exceptions one conditions. Additional permissions applicable entire Program shall treated though included License, extent valid applicable law. additional permissions apply part Program, part may used separately permissions, entire Program remains governed License without regard additional permissions. convey copy covered work, may option remove additional permissions copy, part . (Additional permissions may written require removal certain cases modify work.) may place additional permissions material, added covered work, can give appropriate copyright permission. Notwithstanding provision License, material add covered work, may (authorized copyright holders material) supplement terms License terms: Disclaiming warranty limiting liability differently terms sections 15 16 License; Requiring preservation specified reasonable legal notices author attributions material Appropriate Legal Notices displayed works containing ; Prohibiting misrepresentation origin material, requiring modified versions material marked reasonable ways different original version; Limiting use publicity purposes names licensors authors material; Declining grant rights trademark law use trade names, trademarks, service marks; Requiring indemnification licensors authors material anyone conveys material (modified versions ) contractual assumptions liability recipient, liability contractual assumptions directly impose licensors authors. non-permissive additional terms considered “restrictions” within meaning section 10. Program received , part , contains notice stating governed License along term restriction, may remove term. license document contains restriction permits relicensing conveying License, may add covered work material governed terms license document, provided restriction survive relicensing conveying. add terms covered work accord section, must place, relevant source files, statement additional terms apply files, notice indicating find applicable terms. Additional terms, permissive non-permissive, may stated form separately written license, stated exceptions; requirements apply either way.","code":""},{"path":"https://www.pattern.institute/alz/LICENSE.html","id":"id_8-termination","dir":"","previous_headings":"TERMS AND CONDITIONS","what":"8. Termination.","title":"GNU Affero General Public License","text":"may propagate modify covered work except expressly provided License. attempt otherwise propagate modify void, automatically terminate rights License (including patent licenses granted third paragraph section 11). However, cease violation License, license particular copyright holder reinstated () provisionally, unless copyright holder explicitly finally terminates license, (b) permanently, copyright holder fails notify violation reasonable means prior 60 days cessation. Moreover, license particular copyright holder reinstated permanently copyright holder notifies violation reasonable means, first time received notice violation License (work) copyright holder, cure violation prior 30 days receipt notice. Termination rights section terminate licenses parties received copies rights License. rights terminated permanently reinstated, qualify receive new licenses material section 10.","code":""},{"path":"https://www.pattern.institute/alz/LICENSE.html","id":"id_9-acceptance-not-required-for-having-copies","dir":"","previous_headings":"TERMS AND CONDITIONS","what":"9. Acceptance Not Required for Having Copies.","title":"GNU Affero General Public License","text":"required accept License order receive run copy Program. Ancillary propagation covered work occurring solely consequence using peer--peer transmission receive copy likewise require acceptance. However, nothing License grants permission propagate modify covered work. actions infringe copyright accept License. Therefore, modifying propagating covered work, indicate acceptance License .","code":""},{"path":"https://www.pattern.institute/alz/LICENSE.html","id":"id_10-automatic-licensing-of-downstream-recipients","dir":"","previous_headings":"TERMS AND CONDITIONS","what":"10. Automatic Licensing of Downstream Recipients.","title":"GNU Affero General Public License","text":"time convey covered work, recipient automatically receives license original licensors, run, modify propagate work, subject License. responsible enforcing compliance third parties License. “entity transaction” transaction transferring control organization, substantially assets one, subdividing organization, merging organizations. propagation covered work results entity transaction, party transaction receives copy work also receives whatever licenses work party’s predecessor interest give previous paragraph, plus right possession Corresponding Source work predecessor interest, predecessor can get reasonable efforts. may impose restrictions exercise rights granted affirmed License. example, may impose license fee, royalty, charge exercise rights granted License, may initiate litigation (including cross-claim counterclaim lawsuit) alleging patent claim infringed making, using, selling, offering sale, importing Program portion .","code":""},{"path":"https://www.pattern.institute/alz/LICENSE.html","id":"id_11-patents","dir":"","previous_headings":"TERMS AND CONDITIONS","what":"11. Patents.","title":"GNU Affero General Public License","text":"“contributor” copyright holder authorizes use License Program work Program based. work thus licensed called contributor’s “contributor version”. contributor’s “essential patent claims” patent claims owned controlled contributor, whether already acquired hereafter acquired, infringed manner, permitted License, making, using, selling contributor version, include claims infringed consequence modification contributor version. purposes definition, “control” includes right grant patent sublicenses manner consistent requirements License. contributor grants non-exclusive, worldwide, royalty-free patent license contributor’s essential patent claims, make, use, sell, offer sale, import otherwise run, modify propagate contents contributor version. following three paragraphs, “patent license” express agreement commitment, however denominated, enforce patent (express permission practice patent covenant sue patent infringement). “grant” patent license party means make agreement commitment enforce patent party. convey covered work, knowingly relying patent license, Corresponding Source work available anyone copy, free charge terms License, publicly available network server readily accessible means, must either (1) cause Corresponding Source available, (2) arrange deprive benefit patent license particular work, (3) arrange, manner consistent requirements License, extend patent license downstream recipients. “Knowingly relying” means actual knowledge , patent license, conveying covered work country, recipient’s use covered work country, infringe one identifiable patents country reason believe valid. , pursuant connection single transaction arrangement, convey, propagate procuring conveyance , covered work, grant patent license parties receiving covered work authorizing use, propagate, modify convey specific copy covered work, patent license grant automatically extended recipients covered work works based . patent license “discriminatory” include within scope coverage, prohibits exercise , conditioned non-exercise one rights specifically granted License. may convey covered work party arrangement third party business distributing software, make payment third party based extent activity conveying work, third party grants, parties receive covered work , discriminatory patent license () connection copies covered work conveyed (copies made copies), (b) primarily connection specific products compilations contain covered work, unless entered arrangement, patent license granted, prior 28 March 2007. Nothing License shall construed excluding limiting implied license defenses infringement may otherwise available applicable patent law.","code":""},{"path":"https://www.pattern.institute/alz/LICENSE.html","id":"id_12-no-surrender-of-others-freedom","dir":"","previous_headings":"TERMS AND CONDITIONS","what":"12. No Surrender of Others’ Freedom.","title":"GNU Affero General Public License","text":"conditions imposed (whether court order, agreement otherwise) contradict conditions License, excuse conditions License. convey covered work satisfy simultaneously obligations License pertinent obligations, consequence may convey . example, agree terms obligate collect royalty conveying convey Program, way satisfy terms License refrain entirely conveying Program.","code":""},{"path":"https://www.pattern.institute/alz/LICENSE.html","id":"id_13-remote-network-interaction-use-with-the-gnu-general-public-license","dir":"","previous_headings":"TERMS AND CONDITIONS","what":"13. Remote Network Interaction; Use with the GNU General Public License.","title":"GNU Affero General Public License","text":"Notwithstanding provision License, modify Program, modified version must prominently offer users interacting remotely computer network (version supports interaction) opportunity receive Corresponding Source version providing access Corresponding Source network server charge, standard customary means facilitating copying software. Corresponding Source shall include Corresponding Source work covered version 3 GNU General Public License incorporated pursuant following paragraph. Notwithstanding provision License, permission link combine covered work work licensed version 3 GNU General Public License single combined work, convey resulting work. terms License continue apply part covered work, work combined remain governed version 3 GNU General Public License.","code":""},{"path":"https://www.pattern.institute/alz/LICENSE.html","id":"id_14-revised-versions-of-this-license","dir":"","previous_headings":"TERMS AND CONDITIONS","what":"14. Revised Versions of this License.","title":"GNU Affero General Public License","text":"Free Software Foundation may publish revised /new versions GNU Affero General Public License time time. new versions similar spirit present version, may differ detail address new problems concerns. version given distinguishing version number. Program specifies certain numbered version GNU Affero General Public License “later version” applies , option following terms conditions either numbered version later version published Free Software Foundation. Program specify version number GNU Affero General Public License, may choose version ever published Free Software Foundation. Program specifies proxy can decide future versions GNU Affero General Public License can used, proxy’s public statement acceptance version permanently authorizes choose version Program. Later license versions may give additional different permissions. However, additional obligations imposed author copyright holder result choosing follow later version.","code":""},{"path":"https://www.pattern.institute/alz/LICENSE.html","id":"id_15-disclaimer-of-warranty","dir":"","previous_headings":"TERMS AND CONDITIONS","what":"15. Disclaimer of Warranty.","title":"GNU Affero General Public License","text":"WARRANTY PROGRAM, EXTENT PERMITTED APPLICABLE LAW. EXCEPT OTHERWISE STATED WRITING COPYRIGHT HOLDERS /PARTIES PROVIDE PROGRAM “” WITHOUT WARRANTY KIND, EITHER EXPRESSED IMPLIED, INCLUDING, LIMITED , IMPLIED WARRANTIES MERCHANTABILITY FITNESS PARTICULAR PURPOSE. ENTIRE RISK QUALITY PERFORMANCE PROGRAM . PROGRAM PROVE DEFECTIVE, ASSUME COST NECESSARY SERVICING, REPAIR CORRECTION.","code":""},{"path":"https://www.pattern.institute/alz/LICENSE.html","id":"id_16-limitation-of-liability","dir":"","previous_headings":"TERMS AND CONDITIONS","what":"16. Limitation of Liability.","title":"GNU Affero General Public License","text":"EVENT UNLESS REQUIRED APPLICABLE LAW AGREED WRITING COPYRIGHT HOLDER, PARTY MODIFIES /CONVEYS PROGRAM PERMITTED , LIABLE DAMAGES, INCLUDING GENERAL, SPECIAL, INCIDENTAL CONSEQUENTIAL DAMAGES ARISING USE INABILITY USE PROGRAM (INCLUDING LIMITED LOSS DATA DATA RENDERED INACCURATE LOSSES SUSTAINED THIRD PARTIES FAILURE PROGRAM OPERATE PROGRAMS), EVEN HOLDER PARTY ADVISED POSSIBILITY DAMAGES.","code":""},{"path":"https://www.pattern.institute/alz/LICENSE.html","id":"id_17-interpretation-of-sections-15-and-16","dir":"","previous_headings":"TERMS AND CONDITIONS","what":"17. Interpretation of Sections 15 and 16.","title":"GNU Affero General Public License","text":"disclaimer warranty limitation liability provided given local legal effect according terms, reviewing courts shall apply local law closely approximates absolute waiver civil liability connection Program, unless warranty assumption liability accompanies copy Program return fee. END TERMS CONDITIONS","code":""},{"path":"https://www.pattern.institute/alz/LICENSE.html","id":"how-to-apply-these-terms-to-your-new-programs","dir":"","previous_headings":"","what":"How to Apply These Terms to Your New Programs","title":"GNU Affero General Public License","text":"develop new program, want greatest possible use public, best way achieve make free software everyone can redistribute change terms. , attach following notices program. safest attach start source file effectively state exclusion warranty; file least “copyright” line pointer full notice found. Also add information contact electronic paper mail. software can interact users remotely computer network, also make sure provides way users get source. example, program web application, interface display “Source” link leads users archive code. many ways offer source, different solutions better different programs; see section 13 specific requirements. also get employer (work programmer) school, , sign “copyright disclaimer” program, necessary. information , apply follow GNU AGPL, see https://www.gnu.org/licenses/.","code":"<one line to give the program's name and a brief idea of what it does.>     Copyright (C) <year>  <name of author>      This program is free software: you can redistribute it and/or modify     it under the terms of the GNU Affero General Public License as     published by the Free Software Foundation, either version 3 of the     License, or (at your option) any later version.      This program is distributed in the hope that it will be useful,     but WITHOUT ANY WARRANTY; without even the implied warranty of     MERCHANTABILITY or FITNESS FOR A PARTICULAR PURPOSE.  See the     GNU Affero General Public License for more details.      You should have received a copy of the GNU Affero General Public License     along with this program.  If not, see <https://www.gnu.org/licenses/>."},{"path":"https://www.pattern.institute/alz/SUPPORT.html","id":null,"dir":"","previous_headings":"","what":"Getting help","title":"Getting help","text":"Thank using alz! GitHub account, please file issue question bug report. GitHub account, can contact Ramiro Magno, maintainer package rmagno@pattern.institute.","code":""},{"path":"https://www.pattern.institute/alz/articles/alz.html","id":"overview","dir":"Articles","previous_headings":"","what":"Overview","title":"alz","text":"alz package provides structured metadata helper functions working Alzheimer’s disease biomarkers. formalizes key concepts related biomarkers measured, interpreted, mapped pathology, using relational data tables. vignette introduces four foundational entities package: analytes: molecular entities quantified assays: measurement implementations used quantify analytes cutpoints: thresholds used interpret assay results biomarkers: biologically clinically meaningful indicators derived one analytes concepts plays distinct role biomarker data model.","code":""},{"path":"https://www.pattern.institute/alz/articles/alz.html","id":"analytes","dir":"Articles","previous_headings":"","what":"Analytes","title":"alz","text":"analyte molecular species quantified. Examples include: Aβ42 (amyloid beta 1–42) p-tau181 (tau phosphorylated threonine 181) GFAP (glial fibrillary acidic protein) Analytes uniquely identified using external ontology references ChEBI UniProt, independent measured interpreted.","code":"analytes()"},{"path":"https://www.pattern.institute/alz/articles/alz.html","id":"assays","dir":"Articles","previous_headings":"","what":"Assays","title":"alz","text":"assay represents specific measurement implementation used quantify analyte. combines: technology (e.g. ELISA, Simoa, PET), platform (e.g. INNOTEST, HD-X), vendor (e.g. Fujirebio, Quanterix), matrix (e.g. CSF, plasma), quantitation properties (e.g. LLOQ, ULOQ, unit). row assays() table reflects specific commercial research-grade measurement system.","code":""},{"path":"https://www.pattern.institute/alz/articles/alz.html","id":"cutpoints","dir":"Articles","previous_headings":"","what":"Cutpoints","title":"alz","text":"cut-point defines numeric assay result discretised categorical levels — negative positive. includes: biomarker classified assay used (optional general) threshold(s) associated labels intended use (e.g. screening vs diagnosis) Cut-points enable classification raw measurements based published validated rules.","code":"cutpoints() #> # A tibble: 9 × 8 #>   cutpt_id             bmk_id cutpoints unit  assay_id intended_use source notes #>   <chr>                <chr>      <dbl> <chr> <chr>    <chr>        <chr>  <chr> #> 1 ab42-csf-elecsys-wi… ab42   1092      pg/mL elecsys… research     10.10… Deri… #> 2 ptau181-ab42-ratio-… ptau1…    0.025  ratio elecsys… research     10.10… Deri… #> 3 ttau-ab42-ratio-csf… ttau-…    0.27   ratio elecsys… research     10.10… Deri… #> 4 ab42-csf-elecsys-ha… ab42   1100      pg/mL elecsys… research     10.10… NA    #> 5 ptau181-ab42-ratio-… ptau1…    0.0215 ratio elecsys… research     10.10… NA    #> 6 ttau-ab42-ratio-csf… ttau-…    0.241  ratio elecsys… research     10.10… NA    #> 7 NA                   NA       NA      NA    NA       NA           NA     NA    #> 8 ab42-innotest        ab42     NA      NA    innotes… diagnosis    PMID:… CSF … #> 9 ptau181-elecsys      ptau1…   NA      NA    elecsys… diagnosis    PMID:… Elec…"},{"path":"https://www.pattern.institute/alz/articles/alz.html","id":"biomarkers","dir":"Articles","previous_headings":"","what":"Biomarkers","title":"alz","text":"biomarker biologically clinically meaningful measurement derived one analytes. Biomarkers may : original: direct assay analyte (e.g. p-tau181 CSF) derived: computed analytes (e.g. Aβ42/Aβ40 ratio, p-tau217 / non-p-tau217) imaging-based: e.g. amyloid PET, FDG PET biomarker mapped : category: core, non-specific, co-pathology subcategory: , T1, T2, N, , V, S modality: fluid, imaging, hybrid","code":"biomarkers() #> # A tibble: 22 × 9 #>    bmk_id     bmk_name bmk_category bmk_class bmk_subclass bmk_modality bmk_type #>    <chr>      <chr>    <chr>        <chr>     <chr>        <chr>        <chr>    #>  1 ab40       Aβ40     core         core 1    A            fluid        original #>  2 ab42       Aβ42     core         core 1    A            fluid        original #>  3 ab42-ab40… Aβ42 / … core         core 1    A            fluid        derived  #>  4 amyloid_p… Amyloid… core         core 1    A            imaging      original #>  5 t-tau      Total t… core         core 1    T1           fluid        original #>  6 ptau217    p-tau217 core         core 1    T1           fluid        original #>  7 ptau181    p-tau181 core         core 1    T1           fluid        original #>  8 ptau231    p-tau231 core         core 1    T1           fluid        original #>  9 ptau181-a… p-tau18… core         core 1    T1           fluid        derived  #> 10 ptau217-n… p-tau21… core         core 1    T1           fluid        derived  #> # ℹ 12 more rows #> # ℹ 2 more variables: analyte_ids <list>, bmk_desc <chr>"},{"path":"https://www.pattern.institute/alz/articles/alz.html","id":"relationships","dir":"Articles","previous_headings":"","what":"Relationships","title":"alz","text":"entities connected follows: Assays measure analytes Biomarkers defined one analytes Cut-points interpret biomarkers, optionally specific assay, intended use mind specific validation circumstances. relational structure allows users navigate molecular data clinical interpretation full transparency.","code":"# Example: get all assays for Aβ42 assays() |> dplyr::filter(analyte_id == \"CHEBI:64647\") #> # A tibble: 8 × 12 #>   assay_id  analyte_id modality matrix cv     lloq  uloq unit  technology vendor #>   <chr>     <chr>      <chr>    <chr>  <lgl> <dbl> <dbl> <chr> <chr>      <chr>  #> 1 innotest… CHEBI:646… fluid    CSF    NA      225  1452 pg/mL ELISA      Fujir… #> 2 lumipuls… CHEBI:646… fluid    CSF    NA       NA    NA pg/mL CLEIA      Fujir… #> 3 euroimmu… CHEBI:646… fluid    CSF    NA       NA    NA pg/mL ELISA      EUROI… #> 4 innogene… CHEBI:646… fluid    CSF    NA       NA    NA pg/mL ELISA      Innog… #> 5 msd-ab42… CHEBI:646… fluid    CSF    NA       NA    NA pg/mL ECLIA      MSD    #> 6 xmap-ab4… CHEBI:646… fluid    CSF    NA       NA    NA pg/mL xMAP       Fujir… #> 7 elecsys-… CHEBI:646… fluid    CSF    NA      150  2500 pg/mL ECLIA      Roche  #> 8 pet-amyl… CHEBI:646… imaging  brain  NA       NA    NA SUVR  PET        AVID   #> # ℹ 2 more variables: platform <chr>, description <chr>"},{"path":"https://www.pattern.institute/alz/articles/history.html","id":"mckhann-et-al--1984-the-clinical-turn","dir":"Articles","previous_headings":"","what":"McKhann et al. (1984): The clinical turn","title":"Redefining Alzheimer's: From Symptoms to Biomarkers","text":"landmark consensus paper, McKhann et al. (1984) established first widely adopted clinical diagnostic criteria Alzheimer’s Disease (AD) joint auspices National Institute Neurological Communicative Disorders Stroke (NINCDS)1 Alzheimer’s Disease Related Disorders Association (ADRDA)2. Briefly, criteria introduced three-tier classification system, reflecting increasing levels diagnostic certainty: Possible AD: cases atypical features presence comorbid conditions contribute dementia, Alzheimer’s disease remains likely diagnosis; Probable AD: clinical diagnosis based insidious onset progressive memory cognitive decline, absence alternative explanations3; Definite AD: requires criteria Probable AD, combined histopathological confirmation Alzheimer’s-specific brain lesions autopsy biopsy. Although grounded clinical observation, framework acknowledged absence specific biomarkers high misclassification rate4 clinical practice.","code":""},{"path":"https://www.pattern.institute/alz/articles/history.html","id":"blacker-et-al--1994-toward-refining-diagnostic-accuracy","dir":"Articles","previous_headings":"","what":"Blacker et al. (1994): Toward refining diagnostic accuracy","title":"Redefining Alzheimer's: From Symptoms to Biomarkers","text":"Blacker et al. (1994) conducted multisite study evaluate reliability validity NINCDS-ADRDA diagnostic criteria Alzheimer’s disease (AD), originally proposed (McKhann et al. 1984). Using autopsy-confirmed diagnoses gold standard, study assessed well clinicians across three academic centers classify 60 cases (AD non-AD) based detailed clinical summaries. findings supported moderate inter-rater reliability good post-consensus validity criteria, also revealed important diagnostic limitations—especially atypical presentations. Key recommendations refining criteria: Early behavioral symptoms (e.g. personality change, disinhibition) often associated non-AD pathologies, Pick’s disease hippocampal sclerosis. authors suggested cases classified probable possible AD future criteria. Prominent early language dysfunction (e.g. progressive aphasia) also frequently corresponded non-AD pathology. authors proposed cases diagnosed possible AD , otherwise typical. distinction probable possible AD showed little difference predictive value, questioning usefulness treating hierarchically distinct terms diagnostic certainty. study highlighted need greater clarity temporal relationships cognitive decline co-occurring neurological psychiatric symptoms, common source diagnostic error. 5 authors advocated future formal revisions criteria incorporate observations—many already reflected clinical judgment experienced diagnosticians. work laid groundwork future revisions AD diagnostic frameworks, including NIA-AA criteria (N) biomarker model, underscoring limits symptom-based classification need refine criteria atypical mixed presentations.","code":""},{"path":[]},{"path":"https://www.pattern.institute/alz/authors.html","id":null,"dir":"","previous_headings":"","what":"Authors","title":"Authors and Citation","text":"Ramiro Magno. Author, maintainer. Miguel Casanova. Author. Pattern Institute. Copyright holder, funder.           https://www.pattern.institute","code":""},{"path":"https://www.pattern.institute/alz/authors.html","id":"citation","dir":"","previous_headings":"","what":"Citation","title":"Authors and Citation","text":"Magno R, Casanova M (2025). alz: Criteria Diagnosis Staging Alzheimer's Disease. R package version 0.0.1, https://www.pattern.institute/alz/.","code":"@Manual{,   title = {alz: Criteria for Diagnosis and Staging of Alzheimer's Disease},   author = {Ramiro Magno and Miguel Casanova},   year = {2025},   note = {R package version 0.0.1},   url = {https://www.pattern.institute/alz/}, }"},{"path":[]},{"path":"https://www.pattern.institute/alz/index.html","id":"installation","dir":"","previous_headings":"","what":"Installation","title":"Criteria for Diagnosis and Staging of Alzheimer's Disease","text":"","code":"# install.packages(\"pak\") pak::pak(\"patterninstitute/alz\")"},{"path":"https://www.pattern.institute/alz/index.html","id":"code-of-conduct","dir":"","previous_headings":"","what":"Code of Conduct","title":"Criteria for Diagnosis and Staging of Alzheimer's Disease","text":"Please note alz project released Contributor Code Conduct. contributing project, agree abide terms.","code":""},{"path":"https://www.pattern.institute/alz/reference/alz-package.html","id":null,"dir":"Reference","previous_headings":"","what":"alz: Criteria for Diagnosis and Staging of Alzheimer's Disease — alz-package","title":"alz: Criteria for Diagnosis and Staging of Alzheimer's Disease — alz-package","text":"Tools representing, organizing, analyzing diagnostic staging information related Alzheimer's disease. Supports structured workflows combining clinical, biological, staging variables consistent reproducible manner. Intended use research, data harmonization, interpretation disease progression frameworks.","code":""},{"path":[]},{"path":"https://www.pattern.institute/alz/reference/alz-package.html","id":"author","dir":"Reference","previous_headings":"","what":"Author","title":"alz: Criteria for Diagnosis and Staging of Alzheimer's Disease — alz-package","text":"Maintainer: Ramiro Magno rmagno@pattern.institute (ORCID) Authors: Miguel Casanova miguel.casanova@firalis.com (ORCID) contributors: Pattern Institute (https://www.pattern.institute) [copyright holder, funder]","code":""},{"path":"https://www.pattern.institute/alz/reference/analytes.html","id":null,"dir":"Reference","previous_headings":"","what":"Alzheimer's disease analytes — analytes","title":"Alzheimer's disease analytes — analytes","text":"Returns tibble containing curated metadata directly measurable analytes relevant Alzheimer's disease research. includes amyloid beta peptides, total tau, phospho-tau isoforms, neurofilament light chain (NfL), GFAP, alpha-synuclein.","code":""},{"path":"https://www.pattern.institute/alz/reference/analytes.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Alzheimer's disease analytes — analytes","text":"","code":"analytes()"},{"path":"https://www.pattern.institute/alz/reference/analytes.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Alzheimer's disease analytes — analytes","text":"tibble following columns: analyte_id Unique identifier analyte. Based ChEBI UniProt, suffixes specificity. analyte_name Concise scientific label (e.g., \"Aβ42\", \"p‐tau181\"). analyte_full_name Expanded form analyte name. molecular_type NCIT concept code corresponding molecular class, e.g. \"peptide\", \"protein\", based NCIT vocabulary. description Brief description analyte's biological function relevance Alzheimer's disease.","code":""},{"path":"https://www.pattern.institute/alz/reference/analytes.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"Alzheimer's disease analytes — analytes","text":"table provides standardized identifiers, human-readable names, molecular types based NCIT terminology, concise descriptions biological relevance. analyte_id values drawn external ontologies ChEBI UniProt, optionally suffixed reflect post-translational modifications (e.g. P10636-pT181) structural fragments (e.g. P10636-MTBR243).","code":""},{"path":[]},{"path":"https://www.pattern.institute/alz/reference/analytes.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Alzheimer's disease analytes — analytes","text":"","code":"analytes() #> # A tibble: 12 × 5 #>    analyte_id     analyte_name analyte_full_name      molecular_type description #>    <chr>          <chr>        <chr>                  <chr>          <chr>       #>  1 CHEBI:64647    Aβ42         Amyloid beta 1-42      C735           42-amino a… #>  2 CHEBI:64646    Aβ40         Amyloid beta 1-40      C735           40-amino a… #>  3 P10636-pT181   p‐tau181     Phosphorylated tau at… C1897          Tau protei… #>  4 P10636-pT202   p‐tau202     Phosphorylated tau at… C1897          Emerging t… #>  5 P10636-pT205   p‐tau205     Phosphorylated tau at… C1897          Tau protei… #>  6 P10636-pT217   p‐tau217     Phosphorylated tau at… C1897          Highly spe… #>  7 P10636-pT231   p‐tau231     Phosphorylated tau at… C1897          Potential … #>  8 P10636-MTBR243 MTBR‐tau243  Microtubule-binding r… C20385         Fragment o… #>  9 P10636         t‐tau        Total tau              C735           Full-lengt… #> 10 P07196         NfL          Neurofilament light c… C735           Axonal dam… #> 11 P14136         GFAP         Glial fibrillary acid… C735           Astrocytic… #> 12 P37840         αSyn         Alpha-synuclein        C735           Presynapti…"},{"path":"https://www.pattern.institute/alz/reference/assay_doc.html","id":null,"dir":"Reference","previous_headings":"","what":"Open assay reference document — assay_doc","title":"Open assay reference document — assay_doc","text":"assay_doc() opens technical fact sheet associated given assay. useful quickly checking specific assay implementations.","code":""},{"path":"https://www.pattern.institute/alz/reference/assay_doc.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Open assay reference document — assay_doc","text":"","code":"assay_doc(assay_id)"},{"path":"https://www.pattern.institute/alz/reference/assay_doc.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Open assay reference document — assay_doc","text":"assay_id character string representing assay identifier (e.g. \"innotest-ab42-csf\"). Check assays() options.","code":""},{"path":"https://www.pattern.institute/alz/reference/assay_doc.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Open assay reference document — assay_doc","text":"Called side effect. Opens PDF document system viewer.","code":""},{"path":"https://www.pattern.institute/alz/reference/assay_doc.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Open assay reference document — assay_doc","text":"","code":"if (FALSE) { # \\dontrun{ assay_doc(\"innotest-ab42-csf\") } # }"},{"path":"https://www.pattern.institute/alz/reference/assays.html","id":null,"dir":"Reference","previous_headings":"","what":"Alzheimer's disease assays — assays","title":"Alzheimer's disease assays — assays","text":"Returns tibble containing curated metadata assay implementations used measure fluid imaging biomarkers relevant Alzheimer's disease research. row describes specific combination vendor, platform, technology used quantify given analyte. Assays represent product-specific implementations (e.g., Elecsys, Simoa HD-X, INNOTEST) produce numeric measurements downstream biomarker classification. Quantitative performance parameters lower upper limits quantification (LLOQ, ULOQ) included available.","code":""},{"path":"https://www.pattern.institute/alz/reference/assays.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Alzheimer's disease assays — assays","text":"","code":"assays()"},{"path":"https://www.pattern.institute/alz/reference/assays.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Alzheimer's disease assays — assays","text":"tibble following columns: assay_id Unique identifier assay. analyte_id Reference measured analyte (see analytes()). modality Either \"fluid\" \"imaging\", denoting type measurement. matrix Biological specimen used, \"CSF\", \"plasma\", \"brain\". cv Coefficient variation. lloq Lower limit quantification, appropriate units. uloq Upper limit quantification. unit Measurement unit (e.g., \"pg/mL\", \"SUVR\"). technology Underlying method used (e.g., \"ELISA\", \"PET\", \"Simoa\"). vendor Manufacturer assay. platform Commercial platform product line name. description Descriptive label assay.","code":""},{"path":[]},{"path":"https://www.pattern.institute/alz/reference/assays.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Alzheimer's disease assays — assays","text":"","code":"assays() #> # A tibble: 22 × 12 #>    assay_id analyte_id modality matrix cv     lloq  uloq unit  technology vendor #>    <chr>    <chr>      <chr>    <chr>  <lgl> <dbl> <dbl> <chr> <chr>      <chr>  #>  1 innotes… CHEBI:646… fluid    CSF    NA    225    1452 pg/mL ELISA      Fujir… #>  2 innotes… CHEBI:646… fluid    CSF    NA      3.4 10000 pg/mL ELISA      Fujir… #>  3 lumipul… CHEBI:646… fluid    CSF    NA     NA      NA pg/mL CLEIA      Fujir… #>  4 lumipul… CHEBI:646… fluid    CSF    NA     NA      NA pg/mL CLEIA      Fujir… #>  5 euroimm… CHEBI:646… fluid    CSF    NA     NA      NA pg/mL ELISA      EUROI… #>  6 euroimm… CHEBI:646… fluid    CSF    NA     NA      NA pg/mL ELISA      EUROI… #>  7 innogen… CHEBI:646… fluid    CSF    NA     NA      NA pg/mL ELISA      Innog… #>  8 innogen… CHEBI:646… fluid    CSF    NA     NA      NA pg/mL ELISA      Innog… #>  9 msd-ab4… CHEBI:646… fluid    CSF    NA     NA      NA pg/mL ECLIA      MSD    #> 10 msd-ab4… CHEBI:646… fluid    CSF    NA     NA      NA pg/mL ECLIA      MSD    #> # ℹ 12 more rows #> # ℹ 2 more variables: platform <chr>, description <chr>"},{"path":"https://www.pattern.institute/alz/reference/bin_by.html","id":null,"dir":"Reference","previous_headings":"","what":"Categorize biomarker values into positivity bins — bin_by","title":"Categorize biomarker values into positivity bins — bin_by","text":"bin_by() converts numeric biomarker values diagnostic categories using one two cut-points. Values equal cut-point assigned higher bin (.e., positive indeterminate), consistent clinical thresholding practices.","code":""},{"path":"https://www.pattern.institute/alz/reference/bin_by.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Categorize biomarker values into positivity bins — bin_by","text":"","code":"bin_by(x, cutpts)"},{"path":"https://www.pattern.institute/alz/reference/bin_by.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Categorize biomarker values into positivity bins — bin_by","text":"x numeric vector biomarker values. cutpts numeric vector one two strictly increasing cut-points.","code":""},{"path":"https://www.pattern.institute/alz/reference/bin_by.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Categorize biomarker values into positivity bins — bin_by","text":"factor levels \"-\", \"+\", \"-\", \"~\", \"+\" depending number cutpts.","code":""},{"path":"https://www.pattern.institute/alz/reference/bin_by.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Categorize biomarker values into positivity bins — bin_by","text":"","code":"# Using one cut-point bin_by(x = 0:10, cutpts = 5) #>  [1] - - - - - + + + + + + #> Levels: - +  # Using two cut-points bin_by(x = 0:10, cutpts = c(5, 7)) #>  [1] - - - - - ~ ~ + + + + #> Levels: - ~ +  # Using cutpoints from the curated table `cutpoints()` bin_by(x = c(800, 1050, 1300), cutpts = cutpts(\"ab42-csf-elecsys-willemse2018\")) #> [1] - - + #> Levels: - +"},{"path":"https://www.pattern.institute/alz/reference/bins.html","id":null,"dir":"Reference","previous_headings":"","what":"An enumeration of bin labels for positivity status — bins","title":"An enumeration of bin labels for positivity status — bins","text":"bins() returns character vector representing levels used classify biomarker values diagnostic bins: \"-\", negative / unimpaired / normal status \"~\", indeterminate / borderline / uncertain status \"+\", positive / impaired / abnormal status","code":""},{"path":"https://www.pattern.institute/alz/reference/bins.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"An enumeration of bin labels for positivity status — bins","text":"","code":"bins(n = 2)"},{"path":"https://www.pattern.institute/alz/reference/bins.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"An enumeration of bin labels for positivity status — bins","text":"n Number levels returned. Use n = 2 binary classification (negative positive). Use n = 3 also include intermediate category (\"~\").","code":""},{"path":"https://www.pattern.institute/alz/reference/bins.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"An enumeration of bin labels for positivity status — bins","text":"character vector length 2 3, representing diagnostic bin labels.","code":""},{"path":"https://www.pattern.institute/alz/reference/bins.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"An enumeration of bin labels for positivity status — bins","text":"","code":"# Use `n = 2` for normal (`\"-\"`) and abnormal (`\"+\"`) bins(n = 2) #> [1] \"-\" \"+\"  # Use `n = 3` to also include the indeterminate category (`\"~\"`) bins(n = 3) #> [1] \"-\" \"~\" \"+\""},{"path":"https://www.pattern.institute/alz/reference/biomarkers.html","id":null,"dir":"Reference","previous_headings":"","what":"Alzheimer's disease biomarkers — biomarkers","title":"Alzheimer's disease biomarkers — biomarkers","text":"Returns tibble curated biomarkers relevant Alzheimer's disease related neurodegenerative conditions. entry represents measurable biological imaging marker, including original analyte-derived biomarkers computed ratios derived indicators.","code":""},{"path":"https://www.pattern.institute/alz/reference/biomarkers.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Alzheimer's disease biomarkers — biomarkers","text":"","code":"biomarkers()"},{"path":"https://www.pattern.institute/alz/reference/biomarkers.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Alzheimer's disease biomarkers — biomarkers","text":"tibble following columns: bmk_id Short identifier biomarker (e.g., \"ab42\", \"ptau181_ab42_ratio\"). bmk_name Human-readable label (e.g., \"Aβ42 / Aβ40\", \"Amyloid PET\"). bmk_category Biomarker classification: \"core\", \"non-specific\", \"co-pathology\". bmk_subcategory ATN co-pathology label: \"\", \"T1\", \"T2\", \"N\", \"\", \"V\", \"S\". bmk_modality Measurement domain: \"fluid\", \"imaging\", \"hybrid\". bmk_type Whether biomarker \"original\" (directly measured) \"derived\" (computed). analyte_ids List analyte IDs used compute define biomarker. bmk_desc Concise description biological relevance measurement rationale. notes Optional comments implementation notes.","code":""},{"path":"https://www.pattern.institute/alz/reference/biomarkers.html","id":"details","dir":"Reference","previous_headings":"","what":"Details","title":"Alzheimer's disease biomarkers — biomarkers","text":"Biomarkers classified according category (e.g., core, non-specific, co-pathology), modality (fluid, imaging), 2024's ATN related subcategory (\"\", \"T1\", \"T2\", \"N\", \"\", \"V\", \"S\"). original derived biomarkers supported, links underlying analyte(s) included provenance.","code":""},{"path":[]},{"path":"https://www.pattern.institute/alz/reference/biomarkers.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Alzheimer's disease biomarkers — biomarkers","text":"","code":"biomarkers() #> # A tibble: 22 × 9 #>    bmk_id     bmk_name bmk_category bmk_class bmk_subclass bmk_modality bmk_type #>    <chr>      <chr>    <chr>        <chr>     <chr>        <chr>        <chr>    #>  1 ab40       Aβ40     core         core 1    A            fluid        original #>  2 ab42       Aβ42     core         core 1    A            fluid        original #>  3 ab42-ab40… Aβ42 / … core         core 1    A            fluid        derived  #>  4 amyloid_p… Amyloid… core         core 1    A            imaging      original #>  5 t-tau      Total t… core         core 1    T1           fluid        original #>  6 ptau217    p-tau217 core         core 1    T1           fluid        original #>  7 ptau181    p-tau181 core         core 1    T1           fluid        original #>  8 ptau231    p-tau231 core         core 1    T1           fluid        original #>  9 ptau181-a… p-tau18… core         core 1    T1           fluid        derived  #> 10 ptau217-n… p-tau21… core         core 1    T1           fluid        derived  #> # ℹ 12 more rows #> # ℹ 2 more variables: analyte_ids <list>, bmk_desc <chr>"},{"path":"https://www.pattern.institute/alz/reference/ci.html","id":null,"dir":"Reference","previous_headings":"","what":"Confidence interval from coefficient of variation — ci","title":"Confidence interval from coefficient of variation — ci","text":"ci() calculates confidence interval around observed values given coefficient variation (CV).","code":""},{"path":"https://www.pattern.institute/alz/reference/ci.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Confidence interval from coefficient of variation — ci","text":"","code":"ci(x, cv, dist = c(\"lognormal\", \"normal\"), level = 0.95)"},{"path":"https://www.pattern.institute/alz/reference/ci.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Confidence interval from coefficient of variation — ci","text":"x numeric vector positive measured values. cv positive scalar: coefficient variation (e.g., 0.10 10%). dist character scalar indicating distributional assumption used compute confidence interval. Must one : \"normal\": assumes measurement errors normally distributed. confidence interval symmetric around observed value. \"lognormal\": assumes measurement errors follow log-normal distribution. results asymmetric confidence interval, often appropriate strictly positive right-skewed measurements (e.g., biomarker concentrations). level Confidence level proportion (e.g., 0.95 95%). Default 0.95.","code":""},{"path":"https://www.pattern.institute/alz/reference/ci.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Confidence interval from coefficient of variation — ci","text":"matrix two columns (lower, upper) one row per element x.","code":""},{"path":"https://www.pattern.institute/alz/reference/ci.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Confidence interval from coefficient of variation — ci","text":"","code":"# Lognormal assumption is often more appropriate for strictly positive # and right-skewed measurements (e.g., biomarker concentrations). ci(c(100, 200), 0.10, dist = \"lognormal\", level = 0.95) #>          lower   upper #> [1,]  82.24159 121.593 #> [2,] 164.48318 243.186  # Normal assumption ci(c(100, 200), 0.10, dist = \"normal\", level = 0.95) #>          lower    upper #> [1,]  80.40036 119.5996 #> [2,] 160.80072 239.1993"},{"path":"https://www.pattern.institute/alz/reference/cutpoints.html","id":null,"dir":"Reference","previous_headings":"","what":"Retrieve biomarker cut-point values or metadata — cutpoints","title":"Retrieve biomarker cut-point values or metadata — cutpoints","text":"cutpoints(): Provides access curated table biomarker cut-points used dichotomise categorise continuous biomarker measurements clinical research settings. cutpts() returns numeric cut-point(s) associated identifier. thresholds typically used classifying biomarker values diagnostic categories positive, negative, indeterminate, see bin_by().","code":""},{"path":"https://www.pattern.institute/alz/reference/cutpoints.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Retrieve biomarker cut-point values or metadata — cutpoints","text":"","code":"cutpoints()  cutpts(cutpt_id)"},{"path":"https://www.pattern.institute/alz/reference/cutpoints.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Retrieve biomarker cut-point values or metadata — cutpoints","text":"cutpt_id character scalar specifying identifier cut-point retrieve.","code":""},{"path":"https://www.pattern.institute/alz/reference/cutpoints.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Retrieve biomarker cut-point values or metadata — cutpoints","text":"cutpoints(): tibble columns cutpt_id, bmk_id, cutpts, unit, assay_id, intended_use, source, notes. cutpts(): numeric value(s) corresponding threshold(s) defined biomarker-assay combination.","code":""},{"path":[]},{"path":"https://www.pattern.institute/alz/reference/cutpoints.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Retrieve biomarker cut-point values or metadata — cutpoints","text":"","code":"# Return the full cut-point table with metadata cutpoints() #> # A tibble: 9 × 8 #>   cutpt_id             bmk_id cutpoints unit  assay_id intended_use source notes #>   <chr>                <chr>      <dbl> <chr> <chr>    <chr>        <chr>  <chr> #> 1 ab42-csf-elecsys-wi… ab42   1092      pg/mL elecsys… research     10.10… Deri… #> 2 ptau181-ab42-ratio-… ptau1…    0.025  ratio elecsys… research     10.10… Deri… #> 3 ttau-ab42-ratio-csf… ttau-…    0.27   ratio elecsys… research     10.10… Deri… #> 4 ab42-csf-elecsys-ha… ab42   1100      pg/mL elecsys… research     10.10… NA    #> 5 ptau181-ab42-ratio-… ptau1…    0.0215 ratio elecsys… research     10.10… NA    #> 6 ttau-ab42-ratio-csf… ttau-…    0.241  ratio elecsys… research     10.10… NA    #> 7 NA                   NA       NA      NA    NA       NA           NA     NA    #> 8 ab42-innotest        ab42     NA      NA    innotes… diagnosis    PMID:… CSF … #> 9 ptau181-elecsys      ptau1…   NA      NA    elecsys… diagnosis    PMID:… Elec…  # Retrieve the numeric cut-point(s) for a specific identifier cutpts(\"ab42-csf-elecsys-willemse2018\") #> [1] 1092 cutpts(\"ptau181-ab42-ratio-csf-elecsys-willemse2018\") #> [1] 0.025"},{"path":"https://www.pattern.institute/alz/reference/cv_cutpts.html","id":null,"dir":"Reference","previous_headings":"","what":"Adjust cut-points using assay precision — cv_cutpts","title":"Adjust cut-points using assay precision — cv_cutpts","text":"Adjusts one two diagnostic cut-points using coefficient variation (CV) account measurement uncertainty. single cut-point provided, expanded confidence interval based expected assay precision. two cut-points given (e.g. defining indeterminate equivocal zone), adjusted independently: lower cut-point defines lower bound, upper cut-point defines upper bound resulting interval. useful applying classification rules continuous biomarker values analytical variability.","code":""},{"path":"https://www.pattern.institute/alz/reference/cv_cutpts.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Adjust cut-points using assay precision — cv_cutpts","text":"","code":"cv_cutpts(cutpts, cv, dist = c(\"lognormal\", \"normal\"), level = 0.95)"},{"path":"https://www.pattern.institute/alz/reference/cv_cutpts.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Adjust cut-points using assay precision — cv_cutpts","text":"cutpts numeric vector length 1 2, representing cut-point(s). cv positive scalar: coefficient variation apply. dist character scalar, either \"normal\" \"lognormal\", indicating distributional assumption used applying CV. level Confidence level use (default = 0.95).","code":""},{"path":"https://www.pattern.institute/alz/reference/cv_cutpts.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Adjust cut-points using assay precision — cv_cutpts","text":"numeric vector length 2: c(lower, upper).","code":""},{"path":"https://www.pattern.institute/alz/reference/cv_cutpts.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Adjust cut-points using assay precision — cv_cutpts","text":"","code":"cv_cutpts(100, cv = 0.1) #>     lower     upper  #>  82.24159 121.59298  cv_cutpts(c(90, 110), cv = 0.1) #> lower.lower upper.upper  #>    74.01743   133.75228"},{"path":"https://www.pattern.institute/alz/reference/loq.html","id":null,"dir":"Reference","previous_headings":"","what":"Limits of quantification per method — loq","title":"Limits of quantification per method — loq","text":"loq() convenience function retrieves limits quantification one assays assays().","code":""},{"path":"https://www.pattern.institute/alz/reference/loq.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Limits of quantification per method — loq","text":"","code":"loq(assay_id)"},{"path":"https://www.pattern.institute/alz/reference/loq.html","id":"arguments","dir":"Reference","previous_headings":"","what":"Arguments","title":"Limits of quantification per method — loq","text":"assay_id method identifier. One values assay_id variable assays().","code":""},{"path":"https://www.pattern.institute/alz/reference/loq.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Limits of quantification per method — loq","text":"named numeric vector two elements: lloq, lower, uloq, upper, limits quantification.","code":""},{"path":"https://www.pattern.institute/alz/reference/loq.html","id":"ref-examples","dir":"Reference","previous_headings":"","what":"Examples","title":"Limits of quantification per method — loq","text":"","code":"# Limits of quantification of Fujirebio INNOTEST β-Amyloid(1-42) CSF ELISA # Check `assays()` for available methods and associated identifiers. loq(assay_id = \"innotest-ab42-csf\") #> lloq uloq  #>  225 1452   # Likewise, for Beta-Amyloid(1-40) loq(assay_id = \"innotest-ab40-csf\") #>    lloq    uloq  #>     3.4 10000.0"},{"path":"https://www.pattern.institute/alz/reference/pkg_name.html","id":null,"dir":"Reference","previous_headings":"","what":"Get package name — pkg_name","title":"Get package name — pkg_name","text":"pkg_name() returns package name.","code":""},{"path":"https://www.pattern.institute/alz/reference/pkg_name.html","id":"ref-usage","dir":"Reference","previous_headings":"","what":"Usage","title":"Get package name — pkg_name","text":"","code":"pkg_name()"},{"path":"https://www.pattern.institute/alz/reference/pkg_name.html","id":"value","dir":"Reference","previous_headings":"","what":"Value","title":"Get package name — pkg_name","text":"Package name character.","code":""}]
